These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20821051)

  • 1. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.
    Masciullo M; Santoro M; Modoni A; Ricci E; Guitton J; Tonali P; Silvestri G
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S355-61. PubMed ID: 20821051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Miglustat therapy in juvenile Sandhoff disease.
    Tallaksen CM; Berg JE
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S289-93. PubMed ID: 19898953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease.
    Villamizar-Schiller IT; Pabón LA; Hufnagel SB; Serrano NC; Karl G; Jefferies JL; Hopkin RJ; Prada CE
    Eur J Med Genet; 2015 Mar; 58(3):180-3. PubMed ID: 25497207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate deprivation therapy in juvenile Sandhoff disease.
    Wortmann SB; Lefeber DJ; Dekomien G; Willemsen MA; Wevers RA; Morava E
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S307-11. PubMed ID: 19898952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Juvenile GM2 gangliosidosis with progressive spinal muscular atrophy onset].
    Rondot P; Navon R; Eymard B; Fardeau M; Turpin JC; Lefevre M; Bathien N; Wu Y; Baumann N
    Rev Neurol (Paris); 1997 Mar; 153(2):120-3. PubMed ID: 9296123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
    Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
    Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substrate reduction therapy in juvenile GM2 gangliosidosis.
    Maegawa GH; Banwell BL; Blaser S; Sorge G; Toplak M; Ackerley C; Hawkins C; Hayes J; Clarke JT
    Mol Genet Metab; 2009; 98(1-2):215-24. PubMed ID: 19595619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adult form of GM2-gangliosidosis: a man and 2 sisters with hexosaminidase-A and -B deficiency (Sandhoff disease) and literature review].
    Schnorf H; Bosshard NU; Gitzelmann R; Spycher MA; Isler P; Waespe W
    Schweiz Med Wochenschr; 1996 May; 126(18):757-64. PubMed ID: 8693300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
    Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
    Maegawa GH; van Giersbergen PL; Yang S; Banwell B; Morgan CP; Dingemanse J; Tifft CJ; Clarke JT
    Mol Genet Metab; 2009 Aug; 97(4):284-91. PubMed ID: 19447653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
    Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
    Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience.
    Fischetto R; Palladino V; Mancardi MM; Giacomini T; Palladino S; Gaeta A; Di Rocco M; Zampini L; Lassandro G; Favia V; Tripaldi ME; Strisciuglio P; Romano A; Severino M; Morrone A; Giordano P
    Mol Genet Genomic Med; 2020 Oct; 8(10):e1371. PubMed ID: 32779865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early and severe sensory loss in three adult siblings with hexosaminidase A and B deficiency (Sandhoff disease).
    Schnorf H; Gitzelmann R; Bosshard NU; Spycher M; Waespe W
    J Neurol Neurosurg Psychiatry; 1995 Nov; 59(5):520-3. PubMed ID: 8530938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil.
    Santos ML; Raskin S; Telles DS; Löhr A; Liberalesso PB; Vieira SC; Cordeiro ML
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S357-61. PubMed ID: 18937049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
    Jeyakumar M; Thomas R; Elliot-Smith E; Smith DA; van der Spoel AC; d'Azzo A; Perry VH; Butters TD; Dwek RA; Platt FM
    Brain; 2003 Apr; 126(Pt 4):974-87. PubMed ID: 12615653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, Imaging, Genetic, and Disease Course Characteristics in Patients With GM2 Gangliosidosis: Beyond Age of Onset.
    Kern J; Böhringer J; Timmann D; Trollmann R; Stendel C; Kamm C; Röbl M; Santhanakumaran V; Groeschel S; Beck-Wödl S; Göricke S; Krägeloh-Mann I; Synofzik M
    Neurology; 2024 Jan; 102(1):e207898. PubMed ID: 38165373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
    Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
    J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine GM2-Gangliosidosis Sandhoff Disease Associated with a 3-Base Pair Deletion in the HEXB Gene.
    Wang P; Henthorn PS; Galban E; Lin G; Takedai T; Casal M
    J Vet Intern Med; 2018 Jan; 32(1):340-347. PubMed ID: 29106755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
    Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
    Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.
    Chiricozzi E; Niemir N; Aureli M; Magini A; Loberto N; Prinetti A; Bassi R; Polchi A; Emiliani C; Caillaud C; Sonnino S
    Mol Neurobiol; 2014 Aug; 50(1):159-67. PubMed ID: 24356898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.